Production (Stage)
Bellicum Pharmaceuticals, Inc.
BLCM
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 89.62% | 8.85% | -30.16% | 14.09% | -80.28% |
| Total Depreciation and Amortization | 0.00% | -33.33% | 50.00% | 100.00% | -66.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -68.30% | 2,413.33% | 96.45% | -156.85% | 138.91% |
| Change in Net Operating Assets | 12.63% | -160.07% | 662.46% | -152.04% | 182.79% |
| Cash from Operations | 81.03% | -24.31% | 6.96% | -17.04% | 10.39% |
| Capital Expenditure | -100.00% | 120.00% | 28.57% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 1,400.00% | 120.00% | 28.57% | -- | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | 90.00% | -400.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 81.22% | -24.20% | 7.00% | -16.97% | 10.37% |